ESR1 and breast cancer: Here, persistent selective targeting of the ERα drives breast cancer progression towards a basal-like ERα-independent disease by depleting chromatin accessibility of ERα and pioneer factor forkhead box protein A1 (FOXA1), and reducing H3K27ac, a mark of active enhancers.